{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2397,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":2397,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"c0ea6a3cf2ea","filters":{"topic":"Multiple Myeloma Research and Treatments"}},"results":[{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.1849845355372984,"gpt":0.4731506599377273,"spread":0.2881661244004289,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002133735,0.0004067827,0.001870439,0.000315903,0.0001335997,0.00004748845,0.000361507,0.000285648,0.0001241684],"category_scores_gemma":[0.001851552,0.0002344533,0.0002290384,0.0001300295,0.0003610278,0.00003178114,0.0002989687,0.0005151417,0.0000265499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008343941,"about_ca_system_score_gemma":0.001063542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001475625,"about_ca_topic_score_gemma":0.0000604884,"domain_scores_codex":[0.9961369,0.001536417,0.0006693133,0.0006260934,0.0003247905,0.0007064535],"domain_scores_gemma":[0.9920589,0.006709743,0.0003040784,0.0005457985,0.00008561104,0.0002958274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02349372,0.0003069696,0.003223959,0.002267292,0.0005630242,0.001824998,0.00007575133,3.189656e-8,0.00004428211,0.0002341926,0.00292003,0.9650458],"study_design_scores_gemma":[0.009628695,0.0007584005,0.04347287,0.005185096,0.0003350485,0.0003392057,0.00003231898,0.00008015893,9.228783e-7,0.000101767,0.9398462,0.0002193752],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01412162,0.9613917,0.00004581392,0.01486226,0.0009585162,0.005429416,0.001496299,0.00008896026,0.001605362],"genre_scores_gemma":[0.01346769,0.9759623,0.005011596,0.0002617118,0.002030201,0.001880135,0.0004590807,0.00008205197,0.000845173],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9648263,"threshold_uncertainty_score":0.9560728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101035019","doi":"10.1038/nature09837","title":"Initial genome sequencing and analysis of multiple myeloma","year":2011,"lang":"en","type":"article","venue":"Nature","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1439,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Multiple Myeloma Research Foundation; National Human Genome Research Institute; National Institute on Aging; Leukaemia and Lymphoma Research; Broad Institute","keywords":"Biology; Multiple myeloma; Gene; Genome; Genetics; Massive parallel sequencing; Mutation; Cancer; Somatic cell; DNA sequencing; Germline mutation; Cancer research; Cancer genome sequencing; Computational biology; Whole genome sequencing; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.04615722236335353,"gpt":0.3260179922858882,"spread":0.2798607699225347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000848708,0.00008639201,0.0002671579,0.0003087579,0.00003333615,0.00000401693,0.00004861472,0.0003529822,0.0002667793],"category_scores_gemma":[0.0001691228,0.00006496136,0.00009353033,0.0004347354,0.0000584113,0.00004481428,0.00003634463,0.0005403286,0.00000565448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004470722,"about_ca_system_score_gemma":0.00005484262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001501245,"about_ca_topic_score_gemma":0.00007835877,"domain_scores_codex":[0.9992905,0.00002280389,0.0001260978,0.0001724094,0.0002188119,0.0001693978],"domain_scores_gemma":[0.9994698,0.00004862765,0.0000417341,0.0001932328,0.0001056388,0.0001410051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008276968,0.000177735,0.942189,0.0001047098,0.003786202,0.0005140785,0.001778564,0.000001477384,0.03772653,0.0001811945,0.00003994241,0.01267286],"study_design_scores_gemma":[0.001279915,0.000157492,0.9849343,0.00001485186,0.0006477449,0.00001781068,0.0001076975,0.0008364614,0.01175352,0.00002912705,0.0001630737,0.00005795663],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938437,0.0008920147,0.0000311882,0.0000397984,0.00002272452,0.0001641909,0.00006504317,0.00001949221,0.004921801],"genre_scores_gemma":[0.996874,0.00004049068,0.002675147,0.0001221068,0.00003303409,0.000005943024,0.0001015184,0.00000851116,0.0001392055],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04274534,"threshold_uncertainty_score":0.2921047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528329272","doi":"10.1056/nejmoa1607751","title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1434,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Otsuka Pharmaceutical; Celgene; Bristol-Myers Squibb; Incyte; Chugai Pharmaceutical; Spectrum Pharmaceuticals; Amgen","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04367413013929703,"gpt":0.3284536669106923,"spread":0.2847795367713952,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009088994,0.0001678525,0.0005875878,0.0002405498,0.00006818615,0.000008188234,0.00008626969,0.00006640881,0.000175704],"category_scores_gemma":[0.003596395,0.0000771272,0.00008991148,0.000102204,0.0001770773,0.0001184691,0.00002238762,0.0001591489,0.000005130702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006457628,"about_ca_system_score_gemma":0.0001656839,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004749931,"about_ca_topic_score_gemma":0.00003810492,"domain_scores_codex":[0.9985124,0.00006990427,0.0004725831,0.0001672157,0.0004718434,0.0003060483],"domain_scores_gemma":[0.9970791,0.00147912,0.0002207665,0.000172536,0.000325562,0.0007229149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01052279,0.00009490341,0.065867,0.00007340157,0.0003634861,0.0004024103,0.0002527402,2.681433e-7,0.04680496,0.0001186985,0.01042505,0.8650743],"study_design_scores_gemma":[0.6016331,0.01107255,0.1419497,0.002080658,0.0005554264,0.006087334,0.0001595545,0.0001182522,0.01458166,0.00191724,0.2196176,0.0002269159],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9536383,0.004640772,0.01139048,0.02861926,0.0004095195,0.0005443614,0.00001484983,0.00001785215,0.0007245772],"genre_scores_gemma":[0.9874772,0.001066544,0.006258802,0.0002473345,0.003040872,0.000005495197,0.000004580656,0.00002326292,0.001875853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8648474,"threshold_uncertainty_score":0.430548,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985864219","doi":"10.1056/nejmoa1411321","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1324,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Oncology; Proteasome inhibitor; Internal medicine; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.03364004799786217,"gpt":0.3132240272849626,"spread":0.2795839792871004,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001495112,0.0001881153,0.0007267118,0.000262089,0.00007781747,0.00001186909,0.0000947878,0.00008337878,0.00009231476],"category_scores_gemma":[0.005404824,0.0001129313,0.000104838,0.0001278976,0.000143915,0.00008673148,0.0000223039,0.0002989073,0.000003691597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005317694,"about_ca_system_score_gemma":0.0001435101,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001206685,"about_ca_topic_score_gemma":0.00004880154,"domain_scores_codex":[0.9983287,0.0001239085,0.0005341221,0.0001825505,0.0005113841,0.000319275],"domain_scores_gemma":[0.996837,0.001577348,0.0002584415,0.0001973873,0.0003445015,0.0007852956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01438454,0.0001575337,0.08649758,0.0002076503,0.0005395822,0.0002522505,0.0007699213,0.000007458058,0.02289151,0.0002440469,0.01350154,0.8605464],"study_design_scores_gemma":[0.6074893,0.01493446,0.1334815,0.001173652,0.0008444079,0.004492134,0.0002679155,0.002620955,0.006667623,0.002121712,0.2256386,0.0002677517],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734291,0.002726479,0.009509334,0.01232368,0.000421,0.0005288944,0.000006472829,0.00001928259,0.001035776],"genre_scores_gemma":[0.9827598,0.0004307501,0.01149982,0.0004768822,0.003719618,0.000005929191,0.00001439103,0.00002819992,0.001064574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8602787,"threshold_uncertainty_score":0.647047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2201190784","doi":"10.1056/nejmoa1505654","title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1320,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Progression-free survival; Oncology; Neutropenia; Hazard ratio; Bortezomib; Dexamethasone; Confidence interval; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.09997258122392107,"gpt":0.365146460681726,"spread":0.265173879457805,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192864,0.0002045445,0.0006724884,0.0002827792,0.0000567035,0.0000104343,0.0001541694,0.00009728847,0.0002426398],"category_scores_gemma":[0.003994416,0.0001035944,0.0001250065,0.0001846728,0.000102477,0.0001276848,0.0000157295,0.0003541995,0.00001306394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00018841,"about_ca_system_score_gemma":0.001054475,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001143347,"about_ca_topic_score_gemma":0.00004614919,"domain_scores_codex":[0.9979272,0.000103167,0.0005958824,0.0001698549,0.0008546905,0.000349141],"domain_scores_gemma":[0.9968585,0.0007526769,0.0003061753,0.0002551719,0.0006706616,0.00115678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0830343,0.0004923183,0.02071968,0.00005567439,0.0006099531,0.001475939,0.001542112,0.000006224208,0.005746967,0.00003172346,0.08036742,0.8059177],"study_design_scores_gemma":[0.4070604,0.02842801,0.01776447,0.0004221195,0.0001519277,0.002377998,0.0004222469,0.0002112159,0.001688399,0.0003793405,0.5409642,0.0001296116],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.968883,0.007562289,0.002040571,0.01669344,0.001149395,0.00113022,0.00001205153,0.00004606634,0.002482928],"genre_scores_gemma":[0.9839585,0.001156667,0.004910728,0.0006533671,0.005014172,0.000009883514,0.00002790636,0.00004096054,0.004227799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8057881,"threshold_uncertainty_score":0.4781977,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021954218","doi":"10.1056/nejmoa070596","title":"Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.03906187277418626,"gpt":0.3303583747850792,"spread":0.291296502010893,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00159268,0.0002100679,0.0008383851,0.0006003605,0.00005113638,0.000006918709,0.0001479251,0.00008047536,0.000126404],"category_scores_gemma":[0.004096923,0.0001339544,0.0001411479,0.0004764091,0.0001366022,0.00009646307,0.00002071029,0.0004909601,0.00000795993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002659187,"about_ca_system_score_gemma":0.0003749391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004439865,"about_ca_topic_score_gemma":0.001635817,"domain_scores_codex":[0.9976386,0.00008028501,0.000877442,0.0001953153,0.0006776921,0.0005306369],"domain_scores_gemma":[0.9965944,0.001722899,0.000351819,0.0002166182,0.0003173986,0.0007968952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03302303,0.000284444,0.2681694,0.0001051286,0.000324905,0.003156835,0.001841704,0.00007736513,0.004925867,0.00001279244,0.004216364,0.6838621],"study_design_scores_gemma":[0.4516118,0.008415214,0.4454495,0.0007123812,0.0002833011,0.001840837,0.0008155563,0.0009038259,0.002043234,0.0001576863,0.08755132,0.0002153051],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760192,0.0020101,0.01536174,0.004920918,0.0003602827,0.0006454967,0.000007069732,0.0000152173,0.0006600001],"genre_scores_gemma":[0.9841912,0.0004153586,0.01141747,0.0005161907,0.002764232,0.000005244777,0.00003659016,0.00003050465,0.0006232517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6836469,"threshold_uncertainty_score":0.5462501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4282033105","doi":"10.1056/nejmoa2203478","title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1114,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Institute of Cancer Research; Hotel Dieu Hospital","funders":"Janssen Research and Development; Winship Cancer Institute; School of Medicine, Stanford University; Cancer Center Amsterdam; Centro de Investigación Biomédica en Red de Cáncer; Eberhard Karls Universität Tübingen; National Cancer Institute; Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona; Emory University; Universidad de Navarra; University College London; Memorial Sloan-Kettering Cancer Center; Perelman School of Medicine, University of Pennsylvania; Universitat de Barcelona; Vrije Universiteit Amsterdam; University of Pennsylvania; University of California, San Francisco; Comprehensive Cancer Center, City of Hope; National Institute for Health and Care Research; Leukemia and Lymphoma Society","keywords":"Multiple myeloma; Refractory (planetary science); Antibody; Cancer research; Antigen; Medicine; CD3; Immunology; Biology; CD8","retraction":null,"screen_n_in":null,"score":{"opus":0.04050119126847216,"gpt":0.323883615450082,"spread":0.2833824241816098,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001272937,0.0001631977,0.0006014087,0.0005886448,0.00009855788,0.000005484233,0.0001798497,0.00004551248,0.002788548],"category_scores_gemma":[0.002021867,0.00009790993,0.00008570418,0.0004572367,0.00008033443,0.00006286137,0.00006521391,0.0009705739,0.000007861531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003599644,"about_ca_system_score_gemma":0.0006219462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003470146,"about_ca_topic_score_gemma":0.000185906,"domain_scores_codex":[0.9974689,0.0002425364,0.0006775157,0.0001706911,0.001107105,0.0003332046],"domain_scores_gemma":[0.9982544,0.000590271,0.0002795499,0.0002384383,0.0001283291,0.0005089954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05035932,0.001246738,0.2275509,0.0001023307,0.0003583538,0.03001059,0.00280844,0.00009432174,0.01217089,0.00004021882,0.02961874,0.6456391],"study_design_scores_gemma":[0.3743024,0.01783746,0.2213432,0.0004940653,0.000164363,0.009463115,0.001579887,0.0004402173,0.0004157374,0.0002249147,0.3735503,0.0001843776],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856879,0.002185607,0.00004642284,0.00932956,0.0005216325,0.000327437,0.000007906572,0.00001641134,0.001877148],"genre_scores_gemma":[0.9934739,0.0002630776,0.000662741,0.0004992412,0.001457274,0.000008588028,0.00001791239,0.00002522557,0.003592008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6454548,"threshold_uncertainty_score":0.998123,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2343386476","doi":"10.1056/nejmoa1516282","title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1054,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; University of Calgary; Hotel Dieu Hospital","funders":"Takeda Oncology","keywords":"Lenalidomide; Ixazomib; Medicine; Multiple myeloma; Dexamethasone; Oncology; Internal medicine; Dermatology; Pharmacology; Carfilzomib","retraction":null,"screen_n_in":null,"score":{"opus":0.05120611506231794,"gpt":0.3360375626803982,"spread":0.2848314476180803,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107806,0.0001778066,0.0006475345,0.0002496955,0.00005807609,0.000008547043,0.00009032714,0.00007108964,0.0002160358],"category_scores_gemma":[0.003812312,0.00008197696,0.00009891432,0.0001039889,0.0001780629,0.0001240628,0.00002443571,0.0001611782,0.000005827524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006968217,"about_ca_system_score_gemma":0.0001876564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000752414,"about_ca_topic_score_gemma":0.00005110226,"domain_scores_codex":[0.9984388,0.00008184713,0.0004937832,0.0001728817,0.0004804825,0.0003322569],"domain_scores_gemma":[0.997041,0.001468252,0.0002234458,0.0001695554,0.0003268123,0.0007709039],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01083302,0.00009609279,0.09096467,0.00006314233,0.0003667243,0.0003582969,0.0002126535,3.048773e-7,0.03989277,0.00008061927,0.009126024,0.8480057],"study_design_scores_gemma":[0.6243415,0.01098499,0.1691242,0.001718582,0.0006149394,0.00525324,0.0001612876,0.0001483198,0.01301766,0.002010656,0.172393,0.0002315415],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.96096,0.002819444,0.00915232,0.02589359,0.0003332306,0.0004785547,0.00001294305,0.0000162147,0.0003336441],"genre_scores_gemma":[0.9855336,0.0009452556,0.008655086,0.000319945,0.002719529,0.000005786466,0.000004785454,0.00002534753,0.001790671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8477741,"threshold_uncertainty_score":0.4563969,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947874495","doi":"10.1056/nejmoa1817249","title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":987,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; University of Calgary","funders":"Janssen Research and Development; National Cancer Institute; Incyte; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical; Amgen","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03083090465145425,"gpt":0.32272611846995,"spread":0.2918952138184958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007512631,0.0001788341,0.0007339016,0.0002674288,0.00005011362,0.00001230232,0.00008378131,0.00007492172,0.0003466068],"category_scores_gemma":[0.0008560343,0.0001041936,0.0000861668,0.0001523081,0.00009418672,0.00009499954,0.00002067757,0.0002746453,0.00001240482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009926206,"about_ca_system_score_gemma":0.0002742813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001175642,"about_ca_topic_score_gemma":0.00002410542,"domain_scores_codex":[0.9985092,0.0000696116,0.000452146,0.0001730082,0.0004958677,0.0003001434],"domain_scores_gemma":[0.9980557,0.0006265852,0.0002204288,0.0001850399,0.0003031996,0.0006090216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05121771,0.0002381676,0.1201409,0.0005190739,0.001737972,0.001603203,0.001721988,0.00002376748,0.03700902,0.0004014504,0.01774562,0.7676411],"study_design_scores_gemma":[0.7467136,0.01769709,0.1058806,0.001818335,0.0009580074,0.008747611,0.0004980383,0.001349428,0.006059785,0.0009654457,0.1090375,0.0002744842],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984702,0.003959769,0.0007852026,0.007697423,0.0003344311,0.0006218995,0.000006452586,0.00001324009,0.001879567],"genre_scores_gemma":[0.9910707,0.0005707598,0.002891176,0.0003120337,0.001753728,0.000003342313,0.00002051452,0.00002459422,0.003353082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7673666,"threshold_uncertainty_score":0.4248892,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015880063","doi":"10.1038/leu.2009.174","title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","year":2009,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Saint John Regional Hospital; Dalhousie University","funders":"National Cancer Institute; National Institute on Aging","keywords":"Multiple myeloma; Chromosomal translocation; Biology; Cancer research; Hematology; Cytogenetics; Comparative genomic hybridization; Gene expression profiling; Gene; Oncology; Genetics; Chromosome; Immunology; Gene expression; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0645365481067835,"gpt":0.3601065434952254,"spread":0.2955699953884419,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003930887,0.0005798784,0.002271626,0.0004249214,0.0000595679,0.00002991821,0.0005230834,0.0004115688,0.000230697],"category_scores_gemma":[0.0005226615,0.0004507757,0.0009739947,0.0006323135,0.00009168199,0.00008162195,0.0001220121,0.0006802281,0.0002605332],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001550754,"about_ca_system_score_gemma":0.0006640792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000021158,"about_ca_topic_score_gemma":0.000003915982,"domain_scores_codex":[0.9963749,0.0002195273,0.001210513,0.0007323002,0.0009852722,0.0004774987],"domain_scores_gemma":[0.9975725,0.0002178918,0.000742404,0.0009641485,0.000206456,0.0002966129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004591035,0.0001492625,0.0001221467,0.02399782,0.0005921386,0.0004746209,0.000007296412,1.023914e-7,0.000058018,0.0002207947,0.001299154,0.9730327],"study_design_scores_gemma":[0.001134454,0.00011949,0.00124161,0.09451959,0.001177029,0.0002743683,0.000002392767,0.00006059337,0.00002547595,0.0000138846,0.9011445,0.0002866048],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004198384,0.9849616,0.0001191466,0.0001618374,0.0002130526,0.002178949,0.00004678159,0.00009041216,0.01218621],"genre_scores_gemma":[0.001073368,0.9928744,0.00218033,0.0001728315,0.0003069321,0.0002675434,0.002344101,0.00009326918,0.0006872409],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9727461,"threshold_uncertainty_score":0.9997944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162771614","doi":"10.1093/annonc/mdx096","title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":872,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"Cilag; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; European Society for Medical Oncology; Bristol-Myers Squibb","keywords":"Medicine; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Asymptomatic; Stage (stratigraphy); Incidence (geometry); Scopus; Internal medicine; MEDLINE; Monoclonal; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.4685253170586109,"gpt":0.5882108824589835,"spread":0.1196855654003726,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.000917163,0.0001766242,0.0007184487,0.0000699017,0.0002485299,0.00002362746,0.0001405619,0.0002115843,0.00002953532],"category_scores_gemma":[0.033564,0.0001271091,0.0002484419,0.00002565305,0.0002982143,0.000163295,0.0001013166,0.00009912005,0.00001938357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000405126,"about_ca_system_score_gemma":0.0003536734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007733858,"about_ca_topic_score_gemma":0.0004157999,"domain_scores_codex":[0.998346,0.0001160958,0.0006244992,0.0003702764,0.0001674638,0.0003757045],"domain_scores_gemma":[0.9944699,0.002559867,0.0004320344,0.0005965131,0.001609228,0.0003324739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003878628,0.001683279,0.2918434,0.00004214383,0.0007871089,0.000153236,0.00006942535,1.917642e-7,0.00005303856,0.00009750508,0.04121346,0.6601785],"study_design_scores_gemma":[0.01890836,0.01452374,0.2553948,0.00005158389,0.0002709453,0.00006930104,0.0001244538,0.0001986308,0.00262385,0.0001477666,0.7075855,0.0001010917],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8743774,0.00258799,0.00005096207,0.1161638,0.0005580933,0.001732767,0.0001241169,0.00002969863,0.004375142],"genre_scores_gemma":[0.9548633,0.01558534,0.02373484,0.003021091,0.0005563953,0.0005358738,0.00006484766,0.00002754774,0.001610767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6663721,"threshold_uncertainty_score":0.9745767,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4211191410","doi":"10.1016/s0140-6736(21)00135-5","title":"Multiple myeloma","year":2021,"lang":"en","type":"review","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Pharmaceuticals; Bayer; Celgene; Takeda Canada; Novartis; Cancer Research UK; Roche Products; Servier; Amgen","keywords":"Multiple myeloma; Medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1541464891673331,"gpt":0.4120173834667758,"spread":0.2578708942994428,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022813,0.0002813131,0.002349392,0.00006087646,0.00009269226,0.00004393532,0.0003167246,0.0001514792,0.000440124],"category_scores_gemma":[0.0004303848,0.0001380609,0.0004956599,0.0002654216,0.00006984918,0.00001824588,0.0001536712,0.0005526787,0.00100535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001052055,"about_ca_system_score_gemma":0.0003429059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002593513,"about_ca_topic_score_gemma":0.00001181846,"domain_scores_codex":[0.9984104,0.0002160355,0.0002664415,0.0003068945,0.0003354328,0.0004648091],"domain_scores_gemma":[0.9980651,0.0004001412,0.00009602914,0.001227925,0.00005642405,0.0001544498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002393031,0.0000626552,0.0001381332,0.006160517,0.0006090368,0.0004818695,0.00001514648,1.689481e-8,2.292718e-7,0.00007818003,0.02535254,0.9670777],"study_design_scores_gemma":[0.0011523,0.00004568283,0.0002018533,0.008403315,0.0006320631,0.0003334055,0.0000065458,0.000006254704,0.000001877031,0.000008431105,0.9890895,0.000118696],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000007756957,0.9900084,0.000004231089,0.0004835361,0.0001247443,0.0008940094,0.0001262533,0.00006871065,0.008282419],"genre_scores_gemma":[0.00002478417,0.9917258,0.0003552937,0.0001754926,0.001769573,0.0001991445,0.0006275608,0.00005172441,0.005070596],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9669591,"threshold_uncertainty_score":0.9997725,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2229483068","doi":"10.1016/s0140-6736(15)01120-4","title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Royal Victoria Hospital; University of British Columbia; Hôpital Maisonneuve-Rosemont; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Refractory (planetary science); Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Surrogate endpoint; Proteasome inhibitor; Surgery; Gastroenterology; Oncology; Lenalidomide","retraction":null,"screen_n_in":null,"score":{"opus":0.07518314198563648,"gpt":0.3707187301208377,"spread":0.2955355881352012,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003078434,0.0002849491,0.000792686,0.00009618726,0.0001437871,0.00006983925,0.0004215923,0.00007558703,0.0002349417],"category_scores_gemma":[0.0001367647,0.0001164948,0.00004185451,0.0001641031,0.0001347827,0.000321075,0.00005220172,0.0001321274,0.00008346405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002702682,"about_ca_system_score_gemma":0.0001550043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002608416,"about_ca_topic_score_gemma":0.0003393115,"domain_scores_codex":[0.9980188,0.0003083613,0.0002990088,0.0004191315,0.0003831266,0.0005715413],"domain_scores_gemma":[0.9982082,0.0003278881,0.0001196683,0.001022508,0.00007856903,0.0002431365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7898898,0.007909521,0.05646346,0.000006428131,0.0002911776,0.00006931845,0.0002036286,2.203384e-7,0.001245333,0.00001304966,0.0005606022,0.1433475],"study_design_scores_gemma":[0.9138007,0.01783056,0.06039951,0.00008813162,0.00005326976,0.000002935576,0.00001657289,0.00006424351,0.0009361387,0.00003135575,0.00661609,0.0001605629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925457,0.0001148759,0.00002570851,0.001008363,0.0000885045,0.004940249,0.0001713659,0.00005704265,0.001048183],"genre_scores_gemma":[0.996903,0.0001735318,0.000415787,0.0002279281,0.0004317747,0.0006214111,0.0001515043,0.00005021349,0.001024854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1431869,"threshold_uncertainty_score":0.4750519,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.1799697924150374,"gpt":0.430217007053223,"spread":0.2502472146381857,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001539815,0.0003932134,0.001367127,0.0001162901,0.000272709,0.00007722509,0.0003313169,0.0001796521,0.00003468867],"category_scores_gemma":[0.003804973,0.0002168784,0.00003755193,0.0002287128,0.0003588906,0.0002077243,0.000332443,0.0004236436,0.00001037668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000346549,"about_ca_system_score_gemma":0.0005373841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004368147,"about_ca_topic_score_gemma":0.001766696,"domain_scores_codex":[0.9968764,0.0007608347,0.0004359984,0.000698146,0.0004407481,0.0007878339],"domain_scores_gemma":[0.994006,0.003943342,0.0002730564,0.0007137231,0.0004071311,0.0006567886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7683562,0.009908414,0.1072701,0.00008900758,0.001436404,0.0003256808,0.003003528,0.000001307062,0.000165489,0.000009595526,0.001600812,0.1078334],"study_design_scores_gemma":[0.887664,0.04880322,0.04790979,0.00006003766,0.0008842844,0.0000482557,0.002704227,0.001423844,0.00008399731,0.00001817139,0.01011126,0.0002889219],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872988,0.0005953084,0.00008187554,0.0009203106,0.0002280489,0.01010749,0.0001618964,0.00006632349,0.0005398872],"genre_scores_gemma":[0.98487,0.0001966836,0.0125567,0.0002890466,0.0002407238,0.001199077,0.000147125,0.00006606619,0.0004345744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1193078,"threshold_uncertainty_score":0.8844044,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2136541422","doi":"10.1016/s1470-2045(13)70380-2","title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical endpoint; Bortezomib; Population; Thalidomide; Progressive disease; Clinical trial; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.08314179518883183,"gpt":0.3790846202528805,"spread":0.2959428250640487,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001432525,0.0005327829,0.002065135,0.0001767966,0.0003956942,0.0001219174,0.000582161,0.0003379224,0.0003041413],"category_scores_gemma":[0.003678101,0.0003268925,0.0001075404,0.0003210619,0.0005694047,0.0003610788,0.0003428361,0.0006251469,0.0001077757],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006013755,"about_ca_system_score_gemma":0.000656767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001248292,"about_ca_topic_score_gemma":0.0003621623,"domain_scores_codex":[0.9957555,0.0009451378,0.0007030018,0.0008387118,0.0005533803,0.001204285],"domain_scores_gemma":[0.9912619,0.006150706,0.0004756749,0.001070484,0.000411891,0.0006293711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9197107,0.005918957,0.001136986,0.0001117976,0.001179322,0.0001466774,0.0003605913,0.000003167391,0.002494975,0.00004369903,0.004414316,0.0644788],"study_design_scores_gemma":[0.9480376,0.03400479,0.0086432,0.0001011655,0.0005582949,0.00003106027,0.0001260025,0.001099443,0.0005999996,0.0001189203,0.006317708,0.0003618065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790796,0.0004198235,0.000211643,0.002410168,0.000621192,0.01649143,0.000198687,0.0001022131,0.0004652185],"genre_scores_gemma":[0.9681648,0.0002829813,0.02384142,0.0007101689,0.0007880835,0.004763646,0.0005446757,0.0001103264,0.0007938877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06411699,"threshold_uncertainty_score":0.9999183,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995934717","doi":"10.1016/s1470-2045(19)30788-0","title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":796,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Institute for Health and Care Research; Seattle Genetics; GlaxoSmithKline; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Multiple myeloma; Discontinuation; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.1334839683588592,"gpt":0.452415809330682,"spread":0.3189318409718228,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002020129,0.0003414265,0.001497144,0.0001237246,0.0002610252,0.0000591109,0.0007875013,0.0001630135,0.001045239],"category_scores_gemma":[0.001088673,0.0001901133,0.0001113552,0.00024328,0.0001380014,0.000138057,0.0003605974,0.0005302013,0.0006059409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003725667,"about_ca_system_score_gemma":0.0006026983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000351167,"about_ca_topic_score_gemma":0.0006206172,"domain_scores_codex":[0.9967175,0.0007683425,0.0005537908,0.0006408391,0.0003819451,0.0009375958],"domain_scores_gemma":[0.9951255,0.002976893,0.000262796,0.001159649,0.0001828193,0.0002923652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.757389,0.02710988,0.03971574,0.0002178249,0.002056232,0.001308653,0.001732488,0.000004224663,0.01462251,0.000161272,0.01930298,0.1363792],"study_design_scores_gemma":[0.8422973,0.03739494,0.008507567,0.00007439568,0.0004133529,0.0002502195,0.0009601491,0.001773139,0.0008759734,0.00008775864,0.1070882,0.0002769981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739405,0.0002122476,0.0000599618,0.003033272,0.0004411787,0.01478162,0.000141201,0.0001138694,0.007276172],"genre_scores_gemma":[0.9823393,0.0001200998,0.002547291,0.001306519,0.0006666297,0.002088076,0.0001955125,0.00007420656,0.01066238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361022,"threshold_uncertainty_score":0.9998679,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141105112","doi":"10.1056/nejmoa1402551","title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":786,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Dexamethasone; Multiple myeloma; Prednisone; Melphalan; Oncology; Internal medicine; Hematopoietic stem cell transplantation; Transplantation","retraction":null,"screen_n_in":null,"score":{"opus":0.01396461102567876,"gpt":0.2676388465394127,"spread":0.2536742355137339,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006965143,0.000149181,0.0005413112,0.0003282969,0.00002646695,0.000006893903,0.00006406015,0.00004712605,0.00008530486],"category_scores_gemma":[0.0003883544,0.00007889169,0.00002969646,0.0001745674,0.00009646134,0.00008727291,0.000008364132,0.0003023305,0.000002472347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003891145,"about_ca_system_score_gemma":0.00009526834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00019342,"about_ca_topic_score_gemma":0.0001283951,"domain_scores_codex":[0.998556,0.0001036367,0.0003859184,0.0001334679,0.0005706477,0.0002502982],"domain_scores_gemma":[0.998753,0.000332581,0.0001400121,0.0001208403,0.0001502687,0.0005032591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006849572,0.0001362154,0.7945098,0.00005749999,0.0001059967,0.0003318701,0.0004833373,0.000004815511,0.0005018713,0.00002783617,0.0003423814,0.1966488],"study_design_scores_gemma":[0.2155725,0.004514196,0.7727426,0.001026698,0.0001459845,0.0007056759,0.00003805678,0.00008458544,0.0003823976,0.0001757282,0.004530109,0.00008151152],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944189,0.0006646049,0.0006362376,0.003114283,0.00007136667,0.0001847765,0.000001836282,0.000005954477,0.0009020145],"genre_scores_gemma":[0.9969758,0.0003806929,0.001537302,0.0002385461,0.0006913544,0.000001300484,0.00001085355,0.00001535952,0.0001487323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2087229,"threshold_uncertainty_score":0.321711,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2048483323","doi":"10.1182/blood-2014-12-615187","title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":762,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Lenalidomide; Oncology; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03792475166351981,"gpt":0.317462271230351,"spread":0.2795375195668311,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004524403,0.0001803964,0.0002812339,0.000273217,0.00005052357,0.00007758874,0.0001164299,0.00009044287,0.00003299955],"category_scores_gemma":[0.0002656142,0.0001565745,0.00004131762,0.0001941456,0.00005510319,0.0002817347,0.0001097998,0.0001923972,0.00000542722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001470215,"about_ca_system_score_gemma":0.0001724835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001686924,"about_ca_topic_score_gemma":0.0001481879,"domain_scores_codex":[0.9979644,0.0001002724,0.0003790884,0.0004041634,0.0008031097,0.0003489665],"domain_scores_gemma":[0.9989744,0.00006173993,0.0001086601,0.0002942658,0.000164116,0.0003967764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000221368,0.001753383,0.9733465,0.000022269,0.0001555828,0.001797077,0.0002342704,7.55944e-7,0.000118313,0.0001229521,0.00003723266,0.0221903],"study_design_scores_gemma":[0.01255711,0.001435564,0.9841553,0.00007934207,0.00005899885,0.0002329232,0.0003287485,0.0001659325,0.0001357893,0.0001050988,0.0006097093,0.0001354682],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860507,0.0001154218,0.00003697674,0.0001210606,0.0003462748,0.0004968883,0.00001669247,0.000062192,0.01275381],"genre_scores_gemma":[0.9964403,0.00005283753,0.002373536,0.00002756462,0.000310455,0.00007393231,0.0003952033,0.00002537761,0.0003008226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02205484,"threshold_uncertainty_score":0.6384923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166508172","doi":"10.1158/0008-5472.can-03-2876","title":"Genetics and Cytogenetics of Multiple Myeloma","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":686,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"National Cancer Institute","keywords":"Monoclonal gammopathy of undetermined significance; Multiple myeloma; Biology; Chromosomal translocation; Cytogenetics; Genetics; Immunology; Cancer research; Chromosome; Monoclonal; Gene; Antibody; Monoclonal antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.1273650904996298,"gpt":0.4379651948271182,"spread":0.3106001043274884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002698186,0.00009602441,0.0002045957,0.0002063064,0.00009561707,0.0000149335,0.0001014555,0.00007314138,0.00009843578],"category_scores_gemma":[0.0002195931,0.00007900144,0.00004123311,0.0003327986,0.0003911027,0.00002463058,0.0001325348,0.0002485394,0.0000252015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001744329,"about_ca_system_score_gemma":0.0004899612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005929182,"about_ca_topic_score_gemma":0.0001814097,"domain_scores_codex":[0.9983557,0.00005302375,0.000168687,0.0002542371,0.000707662,0.0004606603],"domain_scores_gemma":[0.9988071,0.0001121145,0.00002331781,0.0003192566,0.0004005172,0.0003377204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008794961,0.0003846095,0.568272,0.0004312799,0.0002168808,0.0002125472,0.0005141473,0.00007097453,0.3457108,0.0002789676,0.0002485286,0.08277982],"study_design_scores_gemma":[0.006378264,0.0009021883,0.3755772,0.0001947554,0.0000238427,0.00003582412,0.0001576558,0.0001027871,0.6131493,0.0005111669,0.002868485,0.00009851956],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925699,0.005278893,0.00004936747,0.0006897859,0.0000275969,0.0005605203,0.00003736908,0.00001408742,0.00077254],"genre_scores_gemma":[0.9934749,0.003989311,0.001883685,0.00002766167,0.00009405545,0.00008530555,0.00001033741,0.00002373131,0.0004110198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2674386,"threshold_uncertainty_score":0.3221585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089311432","doi":"10.1182/blood-2012-05-425934","title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":655,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of Calgary; University of Toronto","funders":"National Cancer Institute; Jewish General Hospital; Onyx Pharmaceuticals; University of Alberta; Wake Forest University","keywords":"Carfilzomib; Multiple myeloma; Refractory (planetary science); Medicine; Pomalidomide; Lenalidomide; Oncology; Internal medicine; Materials science","retraction":null,"screen_n_in":null,"score":{"opus":0.02848352810245834,"gpt":0.2876643652637208,"spread":0.2591808371612624,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001587977,0.0001954697,0.0003881119,0.0001921879,0.00004892073,0.0000089095,0.0000609156,0.00006577609,0.00003341689],"category_scores_gemma":[0.0001863781,0.0001403719,0.00003349422,0.0002080009,0.00006127597,0.0001392189,0.0000633877,0.0001666606,0.000008485644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006708079,"about_ca_system_score_gemma":0.00004389559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002396821,"about_ca_topic_score_gemma":0.0001252141,"domain_scores_codex":[0.9983955,0.0001061178,0.0003014719,0.0002702362,0.0004918594,0.0004348309],"domain_scores_gemma":[0.9990034,0.00009617886,0.0001057243,0.0003639076,0.00009086614,0.0003399347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00258495,0.07736052,0.9093176,0.00006401713,0.0003063054,0.00008857243,0.002005789,1.901216e-7,0.002965293,6.982081e-7,0.00002056366,0.005285488],"study_design_scores_gemma":[0.1235969,0.01122738,0.8600217,0.00008932954,0.0002014748,0.000007356677,0.0005779993,0.000009177719,0.004022155,6.271312e-7,0.0001266684,0.0001193011],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977832,0.0003295664,0.000001629311,0.00001385685,0.00003781768,0.001508681,0.00002789575,0.00002418741,0.0002731002],"genre_scores_gemma":[0.9993278,0.00001055082,0.0003571771,0.00001658495,0.00004260646,0.00007181714,0.00005913069,0.00003121631,0.00008311165],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1210119,"threshold_uncertainty_score":0.5724199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127143739","doi":"10.1182/blood.v99.3.731","title":"Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Melphalan; Total body irradiation; Medicine; Transplantation; Conditioning; Surgery; Stem cell; Peripheral Blood Stem Cells; Peripheral blood; Hematopoietic stem cell transplantation; Chemotherapy; Internal medicine; Cyclophosphamide; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01493534316314259,"gpt":0.2591304528636316,"spread":0.244195109700489,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003293387,0.0003127755,0.001430907,0.0004210329,0.0001378563,0.00002894816,0.000120388,0.0001456493,0.0001163694],"category_scores_gemma":[0.0001655033,0.0002239546,0.0003375455,0.0006787473,0.0001712751,0.0001574205,0.00002283699,0.0001985254,0.000001680873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008086859,"about_ca_system_score_gemma":0.00008384742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000689636,"about_ca_topic_score_gemma":0.0004149266,"domain_scores_codex":[0.9972706,0.0003568988,0.0009140129,0.0004303762,0.0006500242,0.0003780169],"domain_scores_gemma":[0.9979218,0.0008469094,0.0005460758,0.0003031906,0.0002151,0.0001669573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3267539,0.005590762,0.653945,0.0002845754,0.003394917,0.000042993,0.007085537,0.0004399572,0.001761301,0.00001005271,0.00002854724,0.0006624932],"study_design_scores_gemma":[0.5838262,0.001930649,0.3884641,0.000118619,0.002965601,0.000006178801,0.0003670304,0.01880024,0.003377635,0.000002988817,0.000001544513,0.0001392545],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952488,0.0003977203,0.000157812,0.00005579092,0.00008570844,0.003662595,0.0002547948,0.00002225254,0.0001145397],"genre_scores_gemma":[0.9981316,0.00008562856,0.0003668703,0.00001527806,0.00007684081,0.0003730793,0.0008097127,0.00003286228,0.0001081622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2654809,"threshold_uncertainty_score":0.9132602,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4385839624","doi":"10.1038/s41591-023-02528-9","title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Genentech; Cilag; Astellas Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Adaptive Biotechnologies; Karyopharm Therapeutics; AstraZeneca España; Sanofi; Legend Biotech; Celgene; Amgen; Pfizer","keywords":"Medicine; Neutropenia; Dosing; Internal medicine; Adverse effect; Clinical endpoint; Multiple myeloma; Anemia; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Lenalidomide; Clinical trial; Surgery; Cancer; Chemotherapy; Immunotherapy; Chimeric antigen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.04440612642337285,"gpt":0.3940585836265068,"spread":0.3496524572031339,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001254242,0.0003876309,0.000877186,0.001087141,0.0001124053,0.00001217695,0.0002512403,0.0006604135,0.0007267564],"category_scores_gemma":[0.011599,0.0002430429,0.0001227824,0.002092904,0.000228896,0.00009217751,0.00009013349,0.001896454,0.0003617248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000274236,"about_ca_system_score_gemma":0.0003347934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002884013,"about_ca_topic_score_gemma":0.0004567606,"domain_scores_codex":[0.9959493,0.0002022489,0.0008383038,0.0007816217,0.001363748,0.0008648054],"domain_scores_gemma":[0.9970019,0.001247437,0.0001567887,0.0008413682,0.0001838087,0.0005687275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6869851,0.002437099,0.001927516,0.0002741806,0.0002480408,0.02114416,0.0009729745,0.000002454734,0.01050445,0.00004959271,0.1317631,0.1436912],"study_design_scores_gemma":[0.814836,0.01395557,0.04674531,0.0007670383,0.0001356466,0.0001302449,0.0004333279,0.001780738,0.001461189,0.00006706626,0.1193748,0.0003130813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735156,0.002060892,0.000004676975,0.01328733,0.001321051,0.002729662,0.0001683859,0.0003956866,0.006516757],"genre_scores_gemma":[0.9815276,0.0006908131,0.0002856482,0.0006876926,0.001453022,0.0001716763,0.00153444,0.0000671523,0.01358192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1433781,"threshold_uncertainty_score":0.9967267,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281628749","doi":"10.1056/nejmoa2204925","title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Knight Cancer Institute, Oregon Health and Science University; Houston Methodist Research Institute; Massachusetts General Hospital; Houston Methodist Hospital; Takeda Oncology; Winship Cancer Institute; State University of New York Upstate Medical University; Moffitt Cancer Center; Ohio State University; Barbara Ann Karmanos Cancer Institute; Comprehensive Cancer Center, City of Hope; Medical Center, University of Pittsburgh; Syracuse University; University of Pittsburgh; Memorial Sloan-Kettering Cancer Center; University of Washington; Roswell Park Cancer Institute; University of Pennsylvania; Celgene; U.S. Department of Veterans Affairs; Wayne State University; Takeda Pharmaceuticals North America; Emory University; Bristol-Myers Squibb; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Lenalidomide; Transplantation; Melphalan; Hazard ratio; Autologous stem-cell transplantation; Surgery; Internal medicine; Bortezomib; Dexamethasone; Hematopoietic stem cell transplantation; Clinical endpoint; Randomized controlled trial; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02580289369441924,"gpt":0.3233462153975102,"spread":0.297543321703091,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008760025,0.0001016485,0.0003332662,0.000288742,0.00006902849,0.000004826917,0.00007186268,0.00002243248,0.0004210029],"category_scores_gemma":[0.0001397283,0.00005997307,0.00003440355,0.0002275812,0.00006689609,0.00005867445,0.00001399957,0.0003806771,6.640968e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006701552,"about_ca_system_score_gemma":0.0001743892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008401515,"about_ca_topic_score_gemma":0.00002635301,"domain_scores_codex":[0.9985684,0.0001458336,0.00036828,0.000112869,0.0006135794,0.0001910614],"domain_scores_gemma":[0.9992976,0.0001353097,0.0001474757,0.00008528371,0.00007914071,0.0002552219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01382034,0.0002366404,0.1876921,0.00005901308,0.00009437541,0.004817662,0.002606184,0.00001064319,0.004429247,0.00005542947,0.003247712,0.7829306],"study_design_scores_gemma":[0.3072765,0.009817421,0.5894858,0.0007267945,0.00008484125,0.01266166,0.0007222563,0.0001827075,0.0007984733,0.0006239361,0.07750122,0.0001183907],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795615,0.005477182,0.0001002452,0.01379672,0.0001713255,0.0002811202,0.00000457294,0.000006451332,0.0006008667],"genre_scores_gemma":[0.9940548,0.004212196,0.0004176487,0.0003481645,0.0005062225,0.000007343799,0.00001464418,0.0000110026,0.0004279808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7828122,"threshold_uncertainty_score":0.4609686,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3111394247","doi":"10.1182/bloodadvances.2020002827","title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","year":2020,"lang":"en","type":"review","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cilag; National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Multiple myeloma; Term (time); Negativity effect; Meta-analysis; Oncology; Internal medicine; Survival analysis; Medicine; Psychology; Developmental psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.04332111366551855,"gpt":0.341869319960231,"spread":0.2985482062947124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003672391,0.0005908171,0.005840371,0.0005236221,0.00005423533,0.000034946,0.0003849214,0.0001328126,0.00009627027],"category_scores_gemma":[0.0006266502,0.0002810051,0.001458893,0.001898579,0.0001193153,0.0002478012,0.0001752049,0.0005067838,0.00000857539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006723835,"about_ca_system_score_gemma":0.0002188728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002602705,"about_ca_topic_score_gemma":0.008955328,"domain_scores_codex":[0.9963573,0.0005841624,0.0008715783,0.0006889646,0.0009516716,0.0005463684],"domain_scores_gemma":[0.9972773,0.001159005,0.0005451494,0.0007140194,0.000123304,0.0001812908],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001345859,0.001668924,0.8151978,0.002090266,0.05345762,0.0001237919,0.00007954464,0.000001848486,5.357849e-8,0.000005526409,2.695312e-7,0.1272397],"study_design_scores_gemma":[0.00521406,0.0004367565,0.8160087,0.000681098,0.1546258,0.000002206287,0.00007253313,0.000009396179,0.000009869166,0.00001064091,0.02259347,0.0003354893],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0196265,0.9770841,0.000006609968,0.00004390997,0.0000225401,0.002373925,0.0006848276,0.00002085709,0.0001367409],"genre_scores_gemma":[0.1825961,0.8155765,0.0003386547,0.00001605615,0.00002799223,0.0006100949,0.0006759451,0.00006046132,0.00009821387],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1629696,"threshold_uncertainty_score":0.9999642,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052645281","doi":"10.1016/j.ccr.2013.08.009","title":"Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bortezomib; Proteasome inhibitor; Multiple myeloma; Endoplasmic reticulum; Proteasome; Cancer research; Plasma cell; Progenitor cell; Unfolded protein response; Biology; Antibody; Immunology; Cell biology; Stem cell","retraction":null,"screen_n_in":null,"score":{"opus":0.01708461497933192,"gpt":0.2672179697081689,"spread":0.250133354728837,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001056113,0.0002643448,0.0003752846,0.00009880545,0.00008046235,0.00004383819,0.0001028348,0.00008078921,0.0004785034],"category_scores_gemma":[0.00006674402,0.0002070996,0.00005393576,0.0002078987,0.0001602286,0.0002380003,0.00006212007,0.0002649046,0.0001595537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003422223,"about_ca_system_score_gemma":0.0002091915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001510739,"about_ca_topic_score_gemma":0.002747866,"domain_scores_codex":[0.99819,0.0000932265,0.000288042,0.0004860905,0.0003617832,0.0005808317],"domain_scores_gemma":[0.9988855,0.0002093461,0.0001034122,0.0003005857,0.0001301307,0.0003710204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.00473816,0.001385533,0.3876332,0.002221703,0.0003565993,0.0006089192,0.006996393,0.000019753,0.5627112,0.00002757533,0.004576533,0.0287244],"study_design_scores_gemma":[0.01107644,0.0003814753,0.5184914,0.0004726409,0.00004414536,0.000005866289,0.0003028563,0.001307881,0.4637721,0.0002734824,0.003529678,0.000341939],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905697,0.003760471,0.00000647811,0.00047839,0.0001321865,0.002884948,0.00007337455,0.00004729722,0.002047145],"genre_scores_gemma":[0.9908522,0.0005433704,0.0009903834,0.000268373,0.0001389189,0.001600691,0.00001274398,0.00004559459,0.005547687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1308583,"threshold_uncertainty_score":0.8445275,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2402003835","doi":"10.1182/blood-2016-03-705210","title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Refractory (planetary science); Carfilzomib; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Pomalidomide; Bortezomib","retraction":null,"screen_n_in":null,"score":{"opus":0.02828968112667683,"gpt":0.3204325270016135,"spread":0.2921428458749366,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001887665,0.0002082731,0.0005319943,0.0001707289,0.0000355781,0.000006007661,0.0001191763,0.0001531052,0.0001434247],"category_scores_gemma":[0.0007184711,0.000102575,0.0001002545,0.0002734707,0.0001554936,0.00009692564,0.00003058542,0.0001848843,0.00004225576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000645687,"about_ca_system_score_gemma":0.0001976755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007386773,"about_ca_topic_score_gemma":0.00009035294,"domain_scores_codex":[0.998044,0.0001629353,0.0005450769,0.0004169286,0.0004544015,0.0003766769],"domain_scores_gemma":[0.9982122,0.0006140324,0.0001569701,0.0005918242,0.0001680324,0.0002570114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02728651,0.009637159,0.9134942,0.00002879848,0.0003774024,0.0001482136,0.0000618077,9.888685e-8,0.0009439565,0.000001755857,0.00005493787,0.04796521],"study_design_scores_gemma":[0.1365806,0.006671669,0.8517203,0.0004184584,0.00007119969,0.000004020893,0.000006526407,0.000006556192,0.004146665,0.000002064956,0.0002591473,0.0001128303],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982246,0.00009560217,0.00001308142,0.00008024874,0.00003906839,0.001107661,0.00004939425,0.00004989392,0.000340409],"genre_scores_gemma":[0.9979445,0.0001060685,0.001161345,0.00003237322,0.00004247388,0.00003405095,0.00004636015,0.00004357381,0.0005892618],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1092941,"threshold_uncertainty_score":0.4182885,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.2558644524284098,"gpt":0.4978180911776169,"spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002752159,0.0003106656,0.002408644,0.0003384835,0.0002767042,0.00009776642,0.001443172,0.0002669843,0.0007839966],"category_scores_gemma":[0.003002085,0.0001727098,0.0001383918,0.0002972493,0.000405315,0.0003382291,0.0004141796,0.0005415448,0.00001458362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00036651,"about_ca_system_score_gemma":0.0008541424,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00424354,"about_ca_topic_score_gemma":0.03634358,"domain_scores_codex":[0.9959409,0.001535458,0.0008072522,0.0006059749,0.0004162975,0.0006940891],"domain_scores_gemma":[0.9954241,0.001209856,0.0006361769,0.002195283,0.0001692113,0.0003653796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9226177,0.008086774,0.005880653,0.00003731708,0.002242309,0.001386143,0.0007441287,0.000006845998,0.007136915,0.000034709,0.0003214163,0.05150512],"study_design_scores_gemma":[0.8935601,0.02472346,0.06643164,0.00004897486,0.001156321,0.0000307837,0.000269325,0.009049005,0.0006584504,0.00003893728,0.003813494,0.000219535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920183,0.00004826544,0.00001557819,0.001027107,0.0004124186,0.002785695,0.0002571335,0.00003847167,0.003397071],"genre_scores_gemma":[0.9957392,0.0001923372,0.001191483,0.0002813523,0.0005518643,0.000355512,0.0003580068,0.00004002802,0.001290266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06055099,"threshold_uncertainty_score":0.9812406,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096672426","doi":"10.1200/jco.2014.57.9961","title":"Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Takeda Oncology; National Institutes of Health; National University Health System; Gachon University; Tel Aviv University; Ostravská Univerzita v Ostravě; Universidad de Salamanca; Eli Lilly and Company; National Taiwan University Hospital; Keio University; Northwestern University; York University; Nagoya City University; Cedars-Sinai Medical Center; University of Arkansas for Medical Sciences; Ankara Universitesi; National Taiwan University; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; University of Alberta; Queen Mary University of London; Universität Wien; Emory University; Gil Medical Center, Gachon University; Universität Heidelberg; Celgene","keywords":"Medicine; Multiple myeloma; Magnetic resonance imaging; Radiology; Plasmacytoma; Bone marrow; Asymptomatic; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0815232574213156,"gpt":0.4278384350591133,"spread":0.3463151776377977,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002551737,0.000092129,0.0007145176,0.0001051284,0.00001152657,0.0000027085,0.0001592725,0.00005400964,0.00001984398],"category_scores_gemma":[0.0007493055,0.00004853278,0.0001169366,0.0001486761,0.0002372705,0.0000332991,0.00005403188,0.0003112661,0.000003036986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001033896,"about_ca_system_score_gemma":0.0005079899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000587847,"about_ca_topic_score_gemma":0.0000556512,"domain_scores_codex":[0.9969376,0.0004201473,0.001611971,0.0001177821,0.0007057012,0.0002068163],"domain_scores_gemma":[0.9971445,0.0009492653,0.0009328279,0.0002009284,0.0005712749,0.0002012652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01067001,0.003033925,0.7514858,0.00003452015,0.00009981681,0.0006256988,0.0002016898,0.000008172702,0.00000976989,0.0000266084,0.0003537882,0.2334502],"study_design_scores_gemma":[0.03137743,0.01045016,0.9464243,0.0001764914,0.0001334299,0.00002907048,0.001229216,0.0002095938,0.00003047128,0.0001333724,0.009768306,0.00003812661],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945918,0.001706668,0.000008764554,0.001209521,0.00007849932,0.0004782695,0.00001003956,0.000001546863,0.001914842],"genre_scores_gemma":[0.9923275,0.0001575658,0.007270427,0.0001410728,0.00004106545,0.000007399783,0.000003041,0.00000757089,0.00004433806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2334121,"threshold_uncertainty_score":0.1979109,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945852816","doi":"10.1016/s1470-2045(19)30152-4","title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Celgene","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Refractory (planetary science); Multiple myeloma; Open label; Oncology; Internal medicine; Thalidomide; Randomized controlled trial; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.07880100858038529,"gpt":0.3826707602881763,"spread":0.303869751707791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001182864,0.0004328364,0.001790038,0.000124672,0.0002236687,0.00008014269,0.0003929042,0.0002199497,0.0002000064],"category_scores_gemma":[0.0009904037,0.0002053072,0.00007162076,0.0002572597,0.0003021592,0.0002227673,0.0001438824,0.0003995273,0.00003175916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002939396,"about_ca_system_score_gemma":0.0006554853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002095204,"about_ca_topic_score_gemma":0.0002730003,"domain_scores_codex":[0.9968541,0.0006150987,0.0005293651,0.0007091686,0.0003936116,0.0008986097],"domain_scores_gemma":[0.9950304,0.003007004,0.0004168356,0.0008520845,0.0003156048,0.0003780899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.938972,0.004497456,0.0242846,0.0001406316,0.001215255,0.0001806479,0.0002340704,0.00000256347,0.0006606058,0.00001741285,0.001443062,0.02835167],"study_design_scores_gemma":[0.9104992,0.06807929,0.005272681,0.0001814191,0.0006534564,0.0001021359,0.00008247628,0.0007664319,0.000390747,0.00001317452,0.01367968,0.0002793688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779234,0.0002022655,0.00009616528,0.001030248,0.00009515249,0.01923356,0.0001390705,0.00008129615,0.001198846],"genre_scores_gemma":[0.9798231,0.0002544149,0.01249786,0.0007517229,0.0002994504,0.002732856,0.0003941474,0.000101689,0.003144834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06358183,"threshold_uncertainty_score":0.8372186,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075175917","doi":"10.1182/blood-2002-06-1675","title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","year":2003,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Chromosomal translocation; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Fibroblast growth factor receptor 3; Biology; Bone marrow; Hazard ratio; Breakpoint; Internal medicine; Exon; Medicine; Molecular biology; Gastroenterology; Pathology; Immunology; Antibody; Monoclonal; Monoclonal antibody; Receptor; Fibroblast growth factor; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.038379939079467,"gpt":0.3103475589323647,"spread":0.2719676198528976,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001205979,0.0002077073,0.0003685641,0.0002377621,0.00005820566,0.000007777892,0.00009884446,0.0001183805,0.0006965213],"category_scores_gemma":[0.0009733635,0.0001647895,0.0001035201,0.0002860654,0.00008271669,0.000193491,0.00003742873,0.0002114498,0.00007920923],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006148838,"about_ca_system_score_gemma":0.0001624017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001778143,"about_ca_topic_score_gemma":0.00008936556,"domain_scores_codex":[0.9982442,0.0001506861,0.0003048205,0.0004099913,0.0004650397,0.0004253031],"domain_scores_gemma":[0.9988375,0.0001801074,0.00009031439,0.0004364603,0.0001418083,0.0003137598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004455379,0.004541153,0.909397,0.00009737612,0.0001264419,0.0004767102,0.001559719,0.000001243167,0.08231644,0.00002688752,0.0001097224,0.0009017557],"study_design_scores_gemma":[0.01288012,0.0008311071,0.5779034,0.0001606493,0.00006282578,0.00003260157,0.0003962833,0.00005593686,0.4070549,0.00007155816,0.0004164165,0.0001342003],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967003,0.0002606468,0.00002227925,0.00004305655,0.00005699317,0.001012484,0.00007166217,0.00003577632,0.001796836],"genre_scores_gemma":[0.9967703,0.00002969568,0.002440273,0.00004830075,0.00004169423,0.00009014439,0.00002742512,0.0000302361,0.0005219683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3314936,"threshold_uncertainty_score":0.762642,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2091773528","doi":"10.1182/blood-2013-11-538835","title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of Alberta; University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Celgene","keywords":"Medicine; Pomalidomide; Lenalidomide; Neutropenia; Multiple myeloma; Internal medicine; Bortezomib; Population; Dexamethasone; Surgery; Febrile neutropenia; Thalidomide; Randomized controlled trial; Phases of clinical research; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01876082933216229,"gpt":0.3065881242718411,"spread":0.2878272949396788,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001456009,0.0002316326,0.0009338212,0.0004127135,0.00005033449,0.0000247944,0.00006906776,0.00008687135,0.00003300362],"category_scores_gemma":[0.002921201,0.0001515945,0.00004648558,0.0003875153,0.0001233576,0.0001002917,0.00004408234,0.0002845214,0.00001074053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006978695,"about_ca_system_score_gemma":0.0001028007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008289237,"about_ca_topic_score_gemma":0.001842507,"domain_scores_codex":[0.9975492,0.0007607678,0.0004686818,0.0004292591,0.0004241087,0.0003679387],"domain_scores_gemma":[0.9977713,0.001469364,0.0001227764,0.0003387881,0.00007887089,0.0002189615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5040025,0.04723401,0.4265726,0.0001496864,0.0004943208,0.002518778,0.001864568,0.000003331303,0.004959366,0.00001492851,0.000009935663,0.01217597],"study_design_scores_gemma":[0.7993569,0.004120437,0.1918495,0.0002014242,0.000184986,0.00005639225,0.0003192164,0.001983228,0.001753527,0.00002261316,0.00001140615,0.0001404074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956639,0.000212406,0.00005258318,0.0001684637,0.00001959984,0.003665443,0.000004936363,0.00004284851,0.0001698006],"genre_scores_gemma":[0.9973475,0.00004664826,0.001751019,0.00005230647,0.00002783702,0.0004844825,0.00004208403,0.00003419368,0.0002139122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2953544,"threshold_uncertainty_score":0.6181843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152124092","doi":"10.1200/jco.2013.48.7934","title":"International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation","year":2014,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Onyx Pharmaceuticals; National University Health System; Nagoya City University; Gil Medical Center, Gachon University; Genentech; Sahlgrenska Universitetssjukhuset; Università degli Studi di Pavia; Keio University; Cedars-Sinai Medical Center; Weill Cornell Medical College; Abbott Laboratories; Queen Mary University of London; University of Pittsburgh; Ankara Universitesi; University of Arkansas for Medical Sciences; Array BioPharma; Tel Aviv University; Gachon University; York University; Northwestern University; Emory University; American Society of Clinical Oncology; Universität Wien; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; National and Kapodistrian University of Athens; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Daiichi-Sankyo; Takeda Oncology; Massachusetts General Hospital; Sanofi; Amgen","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Transplantation; Adverse effect; Lenalidomide; Disease; Anemia; Autologous stem-cell transplantation; Concomitant; Internal medicine; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.1340411982215561,"gpt":0.4758519201022766,"spread":0.3418107218807206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001377454,0.0003411736,0.00298638,0.000241907,0.00009200837,0.00002061178,0.0001998363,0.0003079281,0.00001536121],"category_scores_gemma":[0.0001396436,0.0001734043,0.0008027998,0.00008306872,0.0002261306,0.00003915123,0.00003473046,0.0003329147,0.000001218164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004769188,"about_ca_system_score_gemma":0.0008947229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005673255,"about_ca_topic_score_gemma":0.00002579673,"domain_scores_codex":[0.9958103,0.0003582326,0.002730465,0.0003453259,0.0004283491,0.0003273446],"domain_scores_gemma":[0.9896354,0.005509381,0.003653818,0.0002027671,0.0007852373,0.000213392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01957559,0.0007614676,0.004021038,0.006469491,0.005743888,0.0001568766,0.0001317583,0.000001553036,1.793745e-7,0.00004099978,0.0002316047,0.9628655],"study_design_scores_gemma":[0.03384839,0.03589336,0.00919635,0.002889922,0.009665203,0.00009304732,0.0002390722,0.00001553644,0.00001029988,0.00001256971,0.9079782,0.0001580814],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03387633,0.922648,0.009571438,0.001259234,0.003460409,0.02260214,0.004447453,0.00003581625,0.00209917],"genre_scores_gemma":[0.02917766,0.9605842,0.008793362,0.00006027027,0.0002733996,0.0002865762,0.0005481403,0.00005032787,0.0002260208],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9627075,"threshold_uncertainty_score":0.7071221,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012182672","doi":"10.1016/j.ccr.2008.01.007","title":"AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies","year":2008,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Multiple Myeloma Research Foundation","keywords":"Germinal center; Transgene; Multiple myeloma; Cancer research; Genetically modified mouse; Biology; Center (category theory); Genetics; Immunology; Gene; B cell; Chemistry; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.05248662879118331,"gpt":0.2977271731314316,"spread":0.2452405443402483,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005279174,0.0001300584,0.0002827427,0.0001316711,0.00003196463,0.00000211711,0.00007153085,0.00007513658,0.0002111316],"category_scores_gemma":[0.00002434663,0.0001132133,0.00008596026,0.00009619387,0.0001069536,0.0001323423,0.00001799192,0.0001050868,0.000003499349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002022024,"about_ca_system_score_gemma":0.0003816701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001138152,"about_ca_topic_score_gemma":0.0002847834,"domain_scores_codex":[0.9988351,0.00002845009,0.0002963851,0.0002027756,0.0004074578,0.0002297657],"domain_scores_gemma":[0.9993894,0.00004533806,0.0001031114,0.0001517065,0.0002049848,0.0001054918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001444422,0.0009601932,0.08848848,0.000254211,0.00006102078,0.00003200255,0.00143945,0.0008290737,0.9057256,0.000008139024,0.0000528772,0.0007045366],"study_design_scores_gemma":[0.006629029,0.0002388993,0.098342,0.0001024403,0.00001751954,0.000009546357,0.0001951251,0.00289913,0.8914543,0.00001337501,0.00001545113,0.00008314114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979401,0.0002333908,0.0001896081,0.00009734486,0.00001902344,0.0004318219,0.0006384127,0.00001006254,0.0004402719],"genre_scores_gemma":[0.9978508,0.000323239,0.0005552745,0.00007692346,0.00002803128,0.0001057679,0.000190141,0.00001673961,0.0008530542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01427125,"threshold_uncertainty_score":0.4616705,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3170038569","doi":"10.1016/s0140-6736(21)00592-4","title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"Sanofi Genzyme; Sanofi","keywords":"Carfilzomib; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Population; Oncology; Lenalidomide","retraction":null,"screen_n_in":null,"score":{"opus":0.1055133731748032,"gpt":0.388914458078011,"spread":0.2834010849032078,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009220915,0.0002508837,0.00107928,0.00008397359,0.0001510565,0.0001309667,0.0003102669,0.0001111047,0.0002443585],"category_scores_gemma":[0.003029604,0.0001655613,0.00006833759,0.0003911193,0.0001461121,0.0001015053,0.0002980421,0.000443326,0.00005646901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001124266,"about_ca_system_score_gemma":0.0002603452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003825265,"about_ca_topic_score_gemma":0.0005376586,"domain_scores_codex":[0.9974769,0.0005652061,0.0004218092,0.0004990904,0.0003822085,0.0006547651],"domain_scores_gemma":[0.9974505,0.0012112,0.0001039497,0.0008442442,0.0001113805,0.0002787456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9072596,0.005159969,0.01162848,0.0001537681,0.0005360754,0.002218251,0.001239236,0.000002195819,0.02032816,0.00008958502,0.003807313,0.04757731],"study_design_scores_gemma":[0.9757557,0.0007544903,0.0083507,0.000159048,0.0001364348,0.00008763478,0.0002721852,0.004996797,0.005575037,0.0001011412,0.003631604,0.0001792589],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879231,0.001867268,0.00002179953,0.003830899,0.0001614119,0.003510627,0.00008781315,0.00004833114,0.002548677],"genre_scores_gemma":[0.9916241,0.0005879515,0.004332611,0.0007990187,0.0004637402,0.0003829018,0.0001284942,0.00003813141,0.001643083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06849601,"threshold_uncertainty_score":0.6751392,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015003025","doi":"10.1038/leu.2009.26","title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Dexamethasone; Cyclophosphamide; Bortezomib; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Gastroenterology; Surgery; Toxicity; Phases of clinical research; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.06004671005117541,"gpt":0.3975095953405324,"spread":0.337462885289357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001364448,0.000256363,0.0006688042,0.000235773,0.0001605526,0.00003451868,0.00009053325,0.0002927889,0.0000309156],"category_scores_gemma":[0.006721986,0.0002162758,0.000150249,0.0003245208,0.0001206163,0.0001634442,0.00004302061,0.0004129307,0.00001065021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00045103,"about_ca_system_score_gemma":0.0005855793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004242939,"about_ca_topic_score_gemma":0.00009663782,"domain_scores_codex":[0.9975767,0.000297999,0.0007159333,0.0005873441,0.0002903101,0.0005316758],"domain_scores_gemma":[0.9969276,0.002039902,0.0001456929,0.0003722381,0.0001039872,0.0004105413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6140288,0.002409073,0.02175638,0.00002595974,0.000110327,0.0005592562,0.0002144527,0.000005900174,0.005467028,0.00002923274,0.001085516,0.354308],"study_design_scores_gemma":[0.4827249,0.01652889,0.4913576,0.0000866316,0.00008081678,0.00002755921,0.00006739226,0.001982663,0.004764685,0.0003061279,0.00187237,0.0002003215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945288,0.0004186902,0.0001605885,0.00142777,0.000263532,0.00305512,0.00003659933,0.00007353099,0.00003538168],"genre_scores_gemma":[0.992181,0.000270131,0.005779338,0.0003842868,0.0004241666,0.0002968951,0.0001396767,0.0000285654,0.0004959198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4696012,"threshold_uncertainty_score":0.8819471,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122021478","doi":"10.1182/blood-2005-09-3869","title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":370,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital","funders":"","keywords":"Medicine; Melphalan; Transplantation; Autologous stem-cell transplantation; Multiple myeloma; Surgery; Internal medicine; Regimen; Vincristine; Clinical trial; Stem cell; Cyclophosphamide; Chemotherapy; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01540223359039853,"gpt":0.2671610918165032,"spread":0.2517588582261046,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005431049,0.0006132061,0.001424591,0.0004360893,0.0002023345,0.00004924494,0.0002482867,0.0004661253,0.00001942203],"category_scores_gemma":[0.00002074967,0.000510094,0.0002720267,0.0006719127,0.0001502147,0.0001851158,0.00001564303,0.000581901,0.00001746437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003027277,"about_ca_system_score_gemma":0.0004771034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002952024,"about_ca_topic_score_gemma":0.003007449,"domain_scores_codex":[0.9952637,0.0006440171,0.001305125,0.0009154706,0.0009102449,0.0009614308],"domain_scores_gemma":[0.9977233,0.000633287,0.0006790666,0.0004765285,0.0001911364,0.0002967237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2889658,0.01329797,0.5881867,0.0007208405,0.0005277019,0.001225633,0.003328012,0.0003141338,0.1001449,0.00001555712,0.00007017155,0.003202653],"study_design_scores_gemma":[0.4083323,0.006931001,0.2656853,0.0001491755,0.001237479,0.00009095064,0.0004141102,0.0003499952,0.3164395,0.00001771553,0.00001066028,0.000341796],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903166,0.0007071911,0.0005816655,0.00006367233,0.0001582611,0.006915171,0.0004857682,0.0002185639,0.0005531241],"genre_scores_gemma":[0.9950643,0.0002600391,0.002391032,0.00001235799,0.0001022563,0.0007626742,0.0009067978,0.00009377463,0.0004067306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3225013,"threshold_uncertainty_score":0.9997351,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3206192616","doi":"10.1016/s1470-2045(21)00466-6","title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; Strong","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Multiple myeloma; Open label; Oncology; Internal medicine; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1690328158794252,"gpt":0.4209981267549274,"spread":0.2519653108755022,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003170471,0.000505158,0.002441913,0.0001687859,0.0002814279,0.0001845962,0.0004512852,0.0003670251,0.0001706202],"category_scores_gemma":[0.01127028,0.0003723887,0.0001093464,0.0004326808,0.000533546,0.0002562208,0.0007122263,0.0009255859,0.00003159534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003669758,"about_ca_system_score_gemma":0.0007524182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006295292,"about_ca_topic_score_gemma":0.01304406,"domain_scores_codex":[0.9935451,0.002705195,0.0009985137,0.001139333,0.0005496701,0.001062185],"domain_scores_gemma":[0.9813802,0.01647637,0.0003585722,0.001048259,0.0001956747,0.0005409037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9339141,0.002819474,0.002284417,0.0000432152,0.0009489874,0.004992716,0.0008621325,0.000005408286,0.009313075,0.00008770476,0.00192652,0.04280226],"study_design_scores_gemma":[0.9685075,0.004204177,0.01113447,0.0001563229,0.0003790686,0.0001294405,0.0004142696,0.001354532,0.003180569,0.0003169373,0.009865488,0.0003572745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810101,0.00358643,0.00006402154,0.008128872,0.0007079591,0.003492668,0.0005471398,0.00005961785,0.002403234],"genre_scores_gemma":[0.9827963,0.00467002,0.008669512,0.0008095608,0.001159534,0.0005538255,0.0007194256,0.00006826246,0.0005535481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04244498,"threshold_uncertainty_score":0.9998728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000069677","doi":"10.1038/leu.2009.147","title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":360,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Placebo; Multiple myeloma; Internal medicine; Gastroenterology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04957727320909769,"gpt":0.3301043192462646,"spread":0.2805270460371669,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008720608,0.000375961,0.001234551,0.0001710302,0.00009904275,0.00003553355,0.0001983841,0.0002007528,0.0001717675],"category_scores_gemma":[0.00230197,0.0002050481,0.0001601058,0.0002405194,0.0001372492,0.0001548936,0.00005073718,0.0005056128,0.00001260174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000771089,"about_ca_system_score_gemma":0.0004951502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001784868,"about_ca_topic_score_gemma":0.001239048,"domain_scores_codex":[0.9967149,0.0005421803,0.0008209063,0.0005486265,0.0008621254,0.0005112017],"domain_scores_gemma":[0.9960093,0.002482291,0.000374543,0.0007019367,0.0001316461,0.0003002284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2406759,0.001818214,0.6447126,0.00005963315,0.0007315143,0.0006396993,0.0008884881,0.00001548955,0.005571169,0.00001856155,0.0005741532,0.1042946],"study_design_scores_gemma":[0.1928214,0.004063403,0.7981959,0.000484238,0.0001713209,0.000003486327,0.00004323842,0.00016348,0.003727319,0.00002672931,0.0001102907,0.0001892225],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970112,0.0002867045,0.00003831524,0.0002218464,0.0001443529,0.001851997,0.000210517,0.00003696432,0.0001981151],"genre_scores_gemma":[0.9978054,0.0001382992,0.0004204459,0.0003059165,0.0001466233,0.00004228795,0.0004792441,0.00003900014,0.0006227663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1534833,"threshold_uncertainty_score":0.8361619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2100738529","doi":"10.1200/jco.2012.47.7901","title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Cilag; Celgene; Takeda Oncology; Onyx Pharmaceuticals; Pfizer; Amgen","keywords":"Medicine; Multiple myeloma; Zoledronic acid; Spinal cord compression; Bone disease; Magnetic resonance imaging; Disease; Radiography; Radiology; Bisphosphonate; Surgery; Internal medicine; Osteoporosis; Spinal cord","retraction":null,"screen_n_in":null,"score":{"opus":0.1831751629649877,"gpt":0.4766221856333922,"spread":0.2934470226684045,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009679433,0.0001359758,0.0008145735,0.000143364,0.00008891292,0.00001587423,0.0001809475,0.0001589587,0.0006945811],"category_scores_gemma":[0.003411564,0.00007414536,0.0007501057,0.0001130985,0.0001939304,0.0001139732,0.00003411855,0.0002962735,0.00002930722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002389901,"about_ca_system_score_gemma":0.0004541427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004249229,"about_ca_topic_score_gemma":0.00002418003,"domain_scores_codex":[0.9971485,0.0002298984,0.001873693,0.000167692,0.0003373278,0.0002428661],"domain_scores_gemma":[0.9906099,0.00691811,0.001199703,0.0002243488,0.0005617934,0.0004861518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.004626445,0.005088266,0.1622729,0.00001049397,0.001743213,0.0001415222,0.0001080802,0.00000967774,0.0001376213,0.0001227091,0.003970309,0.8217688],"study_design_scores_gemma":[0.0201649,0.009205356,0.6519864,0.00008627919,0.0004844526,0.00009358367,0.0001521673,0.004371165,0.00004570383,0.0004817745,0.31286,0.00006826099],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9073236,0.001362465,0.001081225,0.08381531,0.002861304,0.001847623,0.00004192929,0.00001796423,0.001648593],"genre_scores_gemma":[0.9853856,0.003091155,0.009316773,0.0003596466,0.0008614807,0.0001016533,0.00004644638,0.00001766833,0.0008195906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8217005,"threshold_uncertainty_score":0.7605175,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2625253716","doi":"10.1038/leu.2017.138","title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Medicine; Internal medicine; Carfilzomib; Oncology; Proteasome inhibitor; Lenalidomide; Refractory (planetary science); Hematology; Natural history; Pomalidomide; Bortezomib; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01825545139266853,"gpt":0.293698689027516,"spread":0.2754432376348475,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002864379,0.0002380055,0.0004473811,0.0001868475,0.0001567614,0.00003032895,0.0002302972,0.00009816822,0.00004975686],"category_scores_gemma":[0.0004769954,0.0001924958,0.0001005858,0.00004015762,0.0002089762,0.0002440816,0.0002622742,0.0003546265,0.00005163478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002151622,"about_ca_system_score_gemma":0.0005314268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001349471,"about_ca_topic_score_gemma":0.00007141929,"domain_scores_codex":[0.9982309,0.00008422496,0.0003477901,0.0004439914,0.0005202277,0.0003728945],"domain_scores_gemma":[0.9981385,0.00005869199,0.0002100171,0.001097922,0.000162458,0.0003323347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008658757,0.00238093,0.6440898,0.0005987409,0.001182372,0.0009841169,0.01888959,0.000001090175,0.2050663,0.00001756633,0.009565456,0.1085653],"study_design_scores_gemma":[0.01158385,0.001251831,0.9746183,0.0002790659,0.00008262097,0.000012721,0.000548155,0.000150109,0.003036104,0.000004803076,0.008232309,0.000200177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942818,0.001264949,0.0000010452,0.0001484605,0.0004378142,0.002065084,0.000007706612,0.00004338324,0.001749818],"genre_scores_gemma":[0.9901871,0.00001654073,0.0004038933,0.00009736788,0.0001558572,0.0001468968,0.00001015976,0.00003858518,0.008943603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3305285,"threshold_uncertainty_score":0.7849751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2928272073","doi":"10.1200/jco.18.02096","title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Multiple myeloma; Randomized controlled trial; Evidence-based medicine; Systematic review; MEDLINE; Intensive care medicine; Evidence-based practice; Family medicine; Quality of life (healthcare); Clinical trial; Oncology; Internal medicine; Alternative medicine; Nursing; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2089278753004978,"gpt":0.5413060471164012,"spread":0.3323781718159034,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004666014,0.0001994559,0.002558691,0.0001548401,0.00002938885,0.000008439392,0.0001134513,0.000453634,0.0002482895],"category_scores_gemma":[0.02313877,0.0001211478,0.0007888899,0.0001142165,0.0003002549,0.0001734337,0.00007897121,0.0006783625,0.00009241917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001739474,"about_ca_system_score_gemma":0.001807774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007763817,"about_ca_topic_score_gemma":0.00002076886,"domain_scores_codex":[0.9929564,0.0009404433,0.004865822,0.0003082922,0.000610421,0.0003186284],"domain_scores_gemma":[0.9856548,0.009116032,0.002754642,0.0003847386,0.001253499,0.0008363419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01411179,0.0093355,0.483981,0.00003500844,0.001587852,0.001664246,0.00005543043,0.000003170841,0.0003805647,0.00004231622,0.002833993,0.4859692],"study_design_scores_gemma":[0.04738744,0.07581912,0.4873115,0.0000731789,0.0006992822,0.001519123,0.0002367342,0.000673329,0.000283019,0.00006279131,0.385836,0.00009851284],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769717,0.001779239,0.0001291636,0.01349027,0.001141138,0.0006602444,0.00001005604,0.00000911314,0.005809056],"genre_scores_gemma":[0.9247008,0.005998571,0.06617981,0.00115619,0.001208962,0.000004742594,0.000008679785,0.0000229698,0.0007192661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4858707,"threshold_uncertainty_score":0.9850897,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3105812043","doi":"10.1016/s0140-6736(20)32292-3","title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Cancer Research UK","keywords":"Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Internal medicine; Population; Clinical trial; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.1084690263159896,"gpt":0.353852140548447,"spread":0.2453831142324574,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009687358,0.0005814129,0.001760412,0.0001425563,0.0002635317,0.0002176424,0.0005331523,0.0001811769,0.0001587707],"category_scores_gemma":[0.001908014,0.0003742995,0.00007289052,0.0005000588,0.0004214538,0.0003634456,0.0003708072,0.0007768993,0.00004838015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001373356,"about_ca_system_score_gemma":0.0002828969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000695655,"about_ca_topic_score_gemma":0.000351072,"domain_scores_codex":[0.9959959,0.0005423031,0.0006800374,0.0009739275,0.0008000786,0.001007754],"domain_scores_gemma":[0.9963743,0.001536528,0.0002638387,0.0008249179,0.000192133,0.0008082655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8937979,0.003851945,0.05190236,0.0001354842,0.0007155323,0.0002179694,0.001356555,0.000002767018,0.00102411,0.00001576857,0.001606573,0.045373],"study_design_scores_gemma":[0.9239312,0.01826327,0.04926987,0.0001610652,0.000398572,0.00001799114,0.0003317055,0.002342781,0.0004937472,0.00001537849,0.004333532,0.0004408313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866751,0.001208753,0.00008851947,0.004443195,0.0001442797,0.006359615,0.000302718,0.00009736353,0.000680409],"genre_scores_gemma":[0.9899471,0.0005533457,0.006657115,0.001236044,0.0006296766,0.0004732242,0.0002996672,0.00009423729,0.0001096348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04493217,"threshold_uncertainty_score":0.9998709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386324983","doi":"10.1038/s41591-023-02491-5","title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"National Cancer Institute; Terry Fox Foundation; Glenmark Pharmaceuticals; University of Calgary; Comprehensive Cancer Center, City of Hope; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Celgene; Genentech; Deutsche Krebshilfe; Rising Tide Foundation; Pfizer; Amgen; Health Research Board; Multiple Myeloma Research Foundation","keywords":"Chimeric antigen receptor; Antigen; Cancer research; Multiple myeloma; Missense mutation; Immunology; Immunotherapy; Biology; Medicine; Mutation; Genetics; Gene; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.02830774918335869,"gpt":0.324962472355331,"spread":0.2966547231719723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004493227,0.0002927485,0.0008200467,0.0007106347,0.00006451974,0.000005803116,0.0002266499,0.0004087228,0.001826041],"category_scores_gemma":[0.001464952,0.000181335,0.0001054342,0.00143412,0.0001748036,0.00007175074,0.00007663744,0.0007432351,0.0001268434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009163521,"about_ca_system_score_gemma":0.0001458891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009069367,"about_ca_topic_score_gemma":0.0003735531,"domain_scores_codex":[0.9974644,0.0001047589,0.0005181276,0.0004452272,0.0009260125,0.0005414294],"domain_scores_gemma":[0.9983456,0.0006024348,0.0001262121,0.000532741,0.0001758359,0.0002171508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.005465912,0.0005174924,0.1449366,0.0002396915,0.0009320714,0.002423223,0.002275832,0.000005485298,0.7960194,0.0002527258,0.005273002,0.04165855],"study_design_scores_gemma":[0.01706718,0.001055177,0.8691146,0.0008539617,0.00007185581,0.00002338614,0.001111339,0.001617674,0.1044542,0.0009967677,0.003433769,0.0002000695],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989061,0.004651282,0.0001156027,0.004096978,0.0004144274,0.0008981479,0.00009867289,0.0001812288,0.0004826704],"genre_scores_gemma":[0.994606,0.001081717,0.001625085,0.0004497305,0.0001918581,0.00005153594,0.0007131754,0.00005435842,0.001226534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7241781,"threshold_uncertainty_score":0.9990864,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2291176625","doi":"10.1158/1535-7163.mct-15-0730","title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","year":2016,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":309,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Discovery Centre","funders":"","keywords":"Venetoclax; Multiple myeloma; Bortezomib; Cancer research; Bcl-xL; Lenalidomide; Medicine; Pharmacology; Biology; Leukemia; Apoptosis; Immunology; Programmed cell death; Chronic lymphocytic leukemia; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.05085372977947655,"gpt":0.3446252469714147,"spread":0.2937715171919382,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700398,0.0002519537,0.0003627703,0.0001437446,0.0001129999,0.000017837,0.000192114,0.0001383634,0.00005020787],"category_scores_gemma":[0.00009257448,0.000136861,0.00008222678,0.0003172403,0.0001960664,0.00007625078,0.0001315351,0.0002168082,0.000008895876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004418952,"about_ca_system_score_gemma":0.0004110673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001100479,"about_ca_topic_score_gemma":0.00004856081,"domain_scores_codex":[0.9978141,0.0003896283,0.0003151462,0.0004559638,0.0005171629,0.0005079631],"domain_scores_gemma":[0.9988443,0.0002882143,0.00009086449,0.0003619322,0.0001742482,0.0002403859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01335628,0.0002602117,0.01048953,0.00004129914,0.0002565126,0.0001315239,0.0007045269,0.0001700738,0.9377111,0.00001303244,0.0001872851,0.03667867],"study_design_scores_gemma":[0.01021761,0.001272627,0.04798023,0.0003911367,0.0001353793,0.00002406743,0.0001005331,0.006512616,0.9279104,0.0001605982,0.005072264,0.0002225767],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889454,0.003409704,0.001896329,0.003294719,0.00007429583,0.002010167,0.0001830834,0.00003873462,0.0001475643],"genre_scores_gemma":[0.9965779,0.0009420507,0.0006395005,0.0007512691,0.00005089333,0.0006091215,0.000009765876,0.00004224913,0.0003772125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0374907,"threshold_uncertainty_score":0.5581031,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989740966","doi":"10.1111/j.1365-2141.2008.07573.x","title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":308,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Medicine; Bortezomib; Peripheral neuropathy; Multiple myeloma; Internal medicine; Guideline; Surgery; Gastroenterology; Oncology; Diabetes mellitus; Pathology; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.03042436538693536,"gpt":0.361632983993509,"spread":0.3312086186065736,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001264354,0.0001449552,0.0010151,0.0002742991,0.00003086951,0.00001097399,0.0002074832,0.00009528508,0.00004432715],"category_scores_gemma":[0.001317771,0.0001011942,0.0002269121,0.0003950353,0.0001555007,0.000112275,0.00001382092,0.0003897841,5.830128e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001331685,"about_ca_system_score_gemma":0.0004162421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006220032,"about_ca_topic_score_gemma":0.0002616167,"domain_scores_codex":[0.9970384,0.0005700606,0.001481912,0.0001839256,0.0004388972,0.0002868437],"domain_scores_gemma":[0.9982498,0.0002681076,0.0007303227,0.000282698,0.0003524023,0.000116687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.525521,0.02940449,0.1960249,0.0005045694,0.0007714494,0.1196104,0.00362699,0.0004461785,0.01794455,0.00006209905,0.001974946,0.1041084],"study_design_scores_gemma":[0.3818423,0.01497316,0.5334686,0.0008189531,0.0001531604,0.06270134,0.0004882791,0.004678361,0.0005592283,0.0001726658,0.00001023296,0.0001337247],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976618,0.0005980214,0.0001281397,0.0004492089,0.00003545969,0.001038281,0.00001796996,0.000004569455,0.00006652959],"genre_scores_gemma":[0.9986946,0.0001046263,0.001057588,0.00005525097,0.00004187535,0.000009117995,0.0000214159,0.000009861143,0.000005648472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3374436,"threshold_uncertainty_score":0.4126581,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2088123597","doi":"10.1182/blood-2004-10-3913","title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":289,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cancer research; MAPK/ERK pathway; Fibroblast growth factor receptor 3; Tyrosine kinase; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cytotoxic T cell; Kinase; Molecular biology; Fibroblast growth factor; Cell biology; Signal transduction; Receptor; In vitro; Cancer; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02464544621906841,"gpt":0.2835323477386202,"spread":0.2588869015195518,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001018639,0.0002705146,0.0004091068,0.0001165211,0.0001916062,0.00002007476,0.0001178764,0.0001160152,0.00004133797],"category_scores_gemma":[0.0003047392,0.0001635062,0.0003240846,0.0001984629,0.0001309848,0.00006077689,0.00003914909,0.00009144216,0.00002471817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001173332,"about_ca_system_score_gemma":0.0002175216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005312993,"about_ca_topic_score_gemma":0.0001830334,"domain_scores_codex":[0.9983544,0.00001661868,0.0003608337,0.0003645993,0.0004183638,0.0004851543],"domain_scores_gemma":[0.9987045,0.0002060614,0.0001064048,0.0005022745,0.0002376647,0.000243126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005592811,0.03156974,0.0250752,0.0003029239,0.002966481,0.000405515,0.0007575637,0.0002177865,0.9111145,0.0002066795,0.000156616,0.02163417],"study_design_scores_gemma":[0.1169818,0.005526473,0.1438147,0.0001495845,0.001060264,0.0001295267,0.0001576167,0.001088751,0.7284619,0.00005597202,0.002331493,0.0002418144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923294,0.002007234,0.00136423,0.0008697158,0.0001826566,0.002649689,0.0004525499,0.00006994828,0.00007462578],"genre_scores_gemma":[0.9870285,0.0001810169,0.01116888,0.00004556882,0.0004083679,0.0004116791,0.0002308704,0.00004638024,0.0004787425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1826526,"threshold_uncertainty_score":0.6667589,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2024971109","doi":"10.1016/j.ijrobp.2005.06.039","title":"Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients","year":2005,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Radiation therapy; Chemotherapy; Multivariate analysis; Cancer; Plasmacytoma; Internal medicine; Surgery; Radiology; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.02095780984225487,"gpt":0.3561254426836296,"spread":0.3351676328413747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002218788,0.0001491545,0.0005473907,0.0001850371,0.00002391388,0.00000540813,0.0001763361,0.0001103472,0.00004355135],"category_scores_gemma":[0.0001671883,0.0001160952,0.0001095165,0.00009243571,0.00006970009,0.0001547454,0.00007501675,0.000285667,0.000001919131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003763979,"about_ca_system_score_gemma":0.0001804426,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002312482,"about_ca_topic_score_gemma":0.0005241966,"domain_scores_codex":[0.998365,0.0001829554,0.0007713421,0.0001612931,0.0003195441,0.0001998948],"domain_scores_gemma":[0.9981626,0.0003140276,0.0007267207,0.0001024452,0.0005894098,0.0001048104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001065113,0.002600536,0.9229335,0.00001602937,0.0008589288,0.00003642817,0.001009789,0.0006164305,0.0001064027,0.00004820011,0.0001006813,0.07060799],"study_design_scores_gemma":[0.02447378,0.001698518,0.9709762,0.0001125435,0.00009059593,0.00001356206,0.0002687482,0.001449006,0.0002777445,0.0001076107,0.0004580474,0.000073578],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978461,0.0002126056,0.00008775436,0.0009436336,0.0003614906,0.0004093992,0.0001059509,0.000005350684,0.00002767069],"genre_scores_gemma":[0.9981269,0.0003139434,0.0008212721,0.0001664671,0.0004721358,0.00001722725,0.00005304341,0.00001431858,0.00001467792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07053442,"threshold_uncertainty_score":0.4734223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2172122039","doi":"10.1200/jco.2008.18.3087","title":"Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research","funders":"National Institute of Neurological Disorders and Stroke; National Eye Institute; Takeda Oncology; Celgene","keywords":"Medicine; Bortezomib; Multiple myeloma; Polyneuropathy; Peripheral neuropathy; Internal medicine; Surgery; Oncology; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.05753808831090486,"gpt":0.3811943247090732,"spread":0.3236562363981684,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001137869,0.0001426657,0.0008826179,0.0001990788,0.0000320066,0.00001184508,0.00005970116,0.000154726,0.000008928803],"category_scores_gemma":[0.003845608,0.0000994177,0.0001008261,0.0001966382,0.0001873295,0.0001064559,0.00002702067,0.0004789348,7.830475e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007447685,"about_ca_system_score_gemma":0.0004658057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008607211,"about_ca_topic_score_gemma":0.00001321819,"domain_scores_codex":[0.9970855,0.0009755376,0.001243403,0.000209731,0.0002718771,0.0002139717],"domain_scores_gemma":[0.9973177,0.001134431,0.0007543621,0.0001486358,0.0002740117,0.0003709061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06518052,0.004271807,0.6448014,0.000024485,0.0001338195,0.006459406,0.000332904,0.00002903063,0.1250701,0.000009793034,0.00001227761,0.1536745],"study_design_scores_gemma":[0.01857629,0.03342117,0.944216,0.0001265964,0.0001497947,0.0008387289,0.00002231224,0.00143763,0.0006355015,0.000006721315,0.0005014855,0.00006778914],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965667,0.0001910155,0.0002063499,0.002432479,0.0000778282,0.0004429383,0.000005210424,0.000007361632,0.00007017054],"genre_scores_gemma":[0.9980597,0.0003677464,0.001005371,0.0004318482,0.00006511437,0.000002326207,0.00001010657,0.00001436651,0.00004336586],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2994146,"threshold_uncertainty_score":0.460383,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2769593282","doi":"10.1182/blood-2017-07-795047","title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary","funders":"National Cancer Institute; Celgene","keywords":"Multiple myeloma; Medicine; Internal medicine; Oncology; Progression-free survival; Overall survival; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.1205824684812269,"gpt":0.4038414628693454,"spread":0.2832589943881185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003057735,0.0001445045,0.0007692074,0.0002008277,0.0001240558,0.00001656898,0.0002164769,0.00005345998,0.00004623078],"category_scores_gemma":[0.0008290727,0.00008105117,0.0004768888,0.00009287029,0.00009272406,0.00004044551,0.00003016227,0.0000471039,0.000002356533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003430481,"about_ca_system_score_gemma":0.0000860743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001617569,"about_ca_topic_score_gemma":0.004850151,"domain_scores_codex":[0.9987934,0.00005716849,0.0003579643,0.0002039112,0.0003466726,0.0002408861],"domain_scores_gemma":[0.9982817,0.0005609989,0.0002148437,0.0007840974,0.00008204801,0.00007634595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0363987,0.01586112,0.9298707,0.00006329419,0.005853459,0.00006671471,0.0007821827,0.000003998908,0.0004350338,0.00002877405,0.00002423604,0.01061178],"study_design_scores_gemma":[0.3376709,0.004181255,0.6492098,0.00001946188,0.002917877,0.000001332493,0.0001213262,0.000738836,0.004847403,0.000009444722,0.0002219895,0.00006038198],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971474,0.00006212058,0.00003209502,0.0004121742,0.00007638019,0.001521829,0.0003936516,0.000005341358,0.0003490168],"genre_scores_gemma":[0.9986027,0.00004207355,0.0003805449,0.00000596943,0.0000556107,0.000257672,0.0001254689,0.000009149569,0.0005207509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3012722,"threshold_uncertainty_score":0.3305171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3134103265","doi":"10.1016/s1470-2045(20)30756-7","title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genesis Pharma; Genentech; National Natural Science Foundation of China; Takeda Pharmaceutical Company; AbbVie; Sanofi; Roche; Novartis; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Clinical trial; Internal medicine; Oncology; Clinical Practice; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1789959106822273,"gpt":0.4230512628501331,"spread":0.2440553521679057,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003804465,0.000322753,0.001908483,0.00008545473,0.0001707754,0.00003047565,0.0003648667,0.0002728726,0.0003254761],"category_scores_gemma":[0.0004218024,0.0001580948,0.0003329431,0.0001889049,0.0002222092,0.00003218933,0.0002104908,0.0004664057,0.00003463414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006861472,"about_ca_system_score_gemma":0.0004392902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002756693,"about_ca_topic_score_gemma":0.0004389192,"domain_scores_codex":[0.9975802,0.0008275612,0.0005605863,0.0004249375,0.0002685942,0.0003380796],"domain_scores_gemma":[0.9940394,0.004572052,0.0004310737,0.000769733,0.00008159036,0.0001062199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002219771,0.0004770063,0.001618996,0.0002075456,0.001959466,0.000200499,0.0002953065,4.724824e-8,0.000008401273,0.0001767717,0.002716313,0.9921176],"study_design_scores_gemma":[0.004014056,0.0005904422,0.002148751,0.001994791,0.001012544,0.0002088196,0.0001505914,0.0000228464,0.00000341396,0.00003367185,0.9897072,0.0001128618],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000760783,0.9882635,0.00001232769,0.006002084,0.0006395791,0.00119376,0.0003501671,0.00003343875,0.00274435],"genre_scores_gemma":[0.002153302,0.9914218,0.001492481,0.0001905312,0.001374572,0.0004163248,0.002309711,0.00004008045,0.0006011995],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9920048,"threshold_uncertainty_score":0.6446918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}